deltatrials
Completed PHASE2 NCT00002594

Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors

Dose-Intensive Melphalan and Cyclophosphamide With Autologous Bone Marrow Rescue for Recurrent Medulloblastoma and Germ Cell Tumors

Sponsor: Children's Oncology Group

Conditions Brain Tumor Central Nervous System Tumor
Interventions Sargramostim autologous bone marrow transplantation bone marrow ablation with stem cell support cyclophosphamide melphalan peripheral blood stem cell transplantation
Updated 7 times since 2017 Last updated: Jul 23, 2014 Started: Sep 30, 1994 Primary completion: Sep 30, 2003 Completion: Mar 31, 2007

Listed as NCT00002594, this PHASE2 trial focuses on Brain Tumor and Central Nervous System Tumor and remains completed. Sponsored by Children's Oncology Group, it has been updated 7 times since 1994, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Sep 1994

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Children's Oncology Group
  • National Cancer Institute (NCI)
Data source: Children's Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Asheville, United States, Atlanta, United States, Baltimore, United States, Bangor, United States, Bern, Switzerland, Birmingham, United States, Boston, United States, Brisbane, Australia, Buffalo, United States and 85 more location s